Biospring is pleased to announce our recent investment in CenExel, a clinical trial site network across the U.S. offering inpatient clinical trials. CenExel has expertise in complex central nervous system (CNS) related therapeutic areas, including psychiatry, neurology, neuro-degeneration, sleep, and analgesia (pain). Biospring is a thematic-focused investor, and CenExel is an investment in our clinical trial outsourced services theme. Biopharma research & development (R&D) spend in 2024 was over $288B, growing at a
